nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.09.2003 | Concise Article

Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from France

verfasst von: J. W. Decousser, P. Pina, F. Picot, P. Y. Allouch

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 9/2003

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study presented here was to evaluate the in vitro activity of faropenem, a new member of the penem class intended for oral administration, compared with 11 other antimicrobial agents against a large number of Streptococcus pneumoniae strains isolated from adults and children with bloodstream infections in France. The minimum inhibitory concentration of faropenem against 90% of the pediatric strains tested was generally one to two dilutions lower than the most potent beta-lactam agents (i.e., 0.5 µg/ml for faropenem vs. 1 for amoxicillin, 1 for cefotaxime and 0.5 µg/ml for ceftriaxone). Against the adult strains, only moxifloxacin had a MIC₉₀ value similar to faropenem (i.e., 0.25 µg/ml for both agents). Faropenem seems to be a promising antimicrobial agent for the treatment of adult and pediatric Streptococcus pneumoniae infections.

Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Wishwa NK (1996) Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 275:134–141CrossRefPubMed

Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, Jorup C, Julander I, Marrie TJ, Mufson MA, Riquelme R, Thalme A, Torres A, Woodhead MA (2000) Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 182:840–847CrossRefPubMed

Kaplan SL, Mason EO Jr (1998) Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 11:628–644PubMed

Spangler SK, Jacobs MR, Appelbaum PC (1994) In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother 38:2902–2904PubMed

Reinert RR, Lutticken R, Lemperle M, Bryskier A (1999) A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43 (Suppl C):5–8CrossRef

Comité de l'Antibiogramme de la Société française de Microbiologie. (2002) Communiqué 2002.http://www.sfm.asso.fr/Sect4/com2002.pdf

Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF (2003) Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000–2001: a comparison with other beta-lactam agents. J Antimicrob Chemother 51:196–199CrossRefPubMed

Von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteraemia. N Engl J Med 344:11–16CrossRefPubMed

Adam D (2002) Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50 (Suppl):1–5

10.

European Antimicrobial Resistance Surveillance System. Database (2002)http://www.earss.rivm.nl/PAGINA/interwebsite/home_earss.html

11.

Felmingham D, Gruneberg RN (2000) The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 45:191–203CrossRefPubMed

12.

Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen IF, Reiss PT, Medeiros AA (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556–564CrossRefPubMed

13.

Waterer GW, Wunderink RG, Jones CB (2000) Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 118:1839–1840CrossRef

14.

Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE (1999) Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 29:321–327PubMed

15.

Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF (2000) Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 30:520–528CrossRefPubMed

16.

Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R (1997) The in-vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother 39:35–43CrossRef

17.

Du Plessis M, Capper TP, Klugman KP (2002) In vitro activity of faropenem against respiratory pathogens. J Antimicrob Chemother 49:575–577CrossRefPubMed

18.

Marchese A, Debbia EA, Bryskier A, Schito GC (1999) Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens. Clin Microbiol Infect 5:282–287PubMed

19.

Schmitz FJ, Boos M, Mayer S, Verhoef J, Milatovic D, Fluit AC (2001) In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae. J Antimicrob Chemother 48:148–152CrossRefPubMed

20.

Gress TW, Yingling KW, Stanek RJ, Mufson MA (1996) Infection with Streptococcus pneumoniae moderately resistant to penicillin does not alter clinical outcome. Infect Dis Clin Prac 5:435–439

21.

Gemmell CG (2001) Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 48:47–52CrossRefPubMed

22.

Maugein J, Guillemot D, Dupont MJ, Fosse T, Laurans G, Roussel-Delvallez M, Thierry J, Vergnaud M, Weber M, Poirier B (2003) Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in eight French counties. Clin Microbiol Infect 9:280–288PubMed

Titel: Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from France
verfasst von: J. W. Decousser
P. Pina
F. Picot
P. Y. Allouch
Publikationsdatum: 01.09.2003
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 9/2003
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-003-0990-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2003

Long-Term Predominance of a Rare Meningococcal Phenotype in a Small Geographical Area

Chronic Bronchitis in Immunocompromised Patients: Association with a Novel Mycoplasma Species

September 2003

Influence of Microbiological Reports on Physician's Choice of Antimicrobial Treatment for Susceptible Pathogens

Helicobacter pylori Genotypes in Russia

High Frequency of Antibiotic-Associated Diarrhea due to Toxin A-Negative, Toxin B-Positive Clostridium difficile in a Hospital in Japan and Risk Factors for Infection